SCS-led team receives VC Award for Research Enterprise

Prof Marcel Nold

A research team led by Professor Marcel Nold from the School of Clinical Sciences at Monash Health (SCS) and Hudson Institute has received Monash University's Vice Chancellor's Award for Research Enterprise in recognition of their collaboration with pharmaceutical company Roche to develop better treatments for a range of inflammatory diseases.

Professor Marcel Nold appointed ECR Coordinator at SCS

Professor Marcel Nold

Congratulations Marcel Nold, Professor of Paediatric Immunology at the Department of Paediatrics,

Monash University and the Hudson Institute, on his appointment to Early Career Researcher (ECR) Coordinator at the School of Clinical Sciences at Monash Health (SCS).

Also a neonatologist at Monash Newborn, Monash Children’s Hospital, Professor Nold has gathered extensive experience as a scientist and clinician working in Germany, the US and, for the past 9 years, in Australia.

“I am looking forward to working with our ECR representatives Dr Xin Du and Dr Aimee Dordevic to support our ECRs such that they achieve, or, even better, exceed their goals in terms of productivity and career aspirations, and enjoy the work it takes to do so,” Professor Nold said.

“This is a wonderful time to be taking on this role, as important changes in the research space are upon us, for example in terms of funding, which need to be taken into account when we advise ECRs.”

“My experience in working with companies in the pharmaceutical and biotech industries, in addition to academic research will be very useful."

Characterising the Maturation of T Cell Polarisation in Preterm and Term Infants and in the Neonatal Chronic Lung Disease Bronchopulmonary Dysplasia

Marcel Nold et al. published in the Journal of Paediatrics and Child Health.

Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation

Claudia Nold-Petry et al. published in Frontiers in Immunology.

Read article here.

Defining T helper cell immunity in bronchopulmonary dysplasia

Marcel Nold, Claudia Nold-Petry et al. published in the Journal of Immunology.

Read article here.

IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia.

Claudia Nold-Petry et al. published in the Journal of Innate Immunity.

Read article here.

First treatment for incurable lung disease in premature babies

Dr Claudia Nold

Hudson Institute researchers have discovered a potential safe and effective treatment for bronchopulmonary dysplasia (BPD), which could save preterm babies from the severe lifelong effects of this incurable premature lung disease.

The researchers, led by Associate Professor Marcel Nold and Dr Claudia Nold together with senior scientist Dr Ina Rudloff at The Ritchie Centre showed that an anti-inflammatory drug, interleukin 1 receptor antagonist (IL-1Ra), could be given as a preventative measure in the hours after birth to prevent the development of BPD.

The findings of the study have just been published in the Journal of Cellular and Molecular Medicine.

A common preterm disease without a cure

Newborn babies’ immature lungs are often unable to cope with the essential and life-saving respiratory support they are placed on in hospital.

Up to 60 per cent of preterm babies develop BPD, an inflammatory lung disease that causes severe injury to the lung tissue and prevents normal lung growth, soon after birth. The more premature a baby is at birth, the higher the risk of BPD. There is currently no safe and effective treatment.

BPD affects the alveoli, the tiny sacs in the lungs that enable the entry of oxygen into the bloodstream, and the clearance of carbon dioxide from the body.

Babies with BPD often suffer lifelong, severe, complications, including impaired neurodevelopment, and are highly susceptible to airway infections that may lead to death.  As a result, some of these babies and their families will require ongoing medical care into childhood, some even into adulthood.

Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia

Claudia Nold-Petry et al. published in the Journal of Cellular and Molecular Medicine.

Read article here.

Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells

Ina Rudloff et al. published in the Journal of Leukocyte Biology.

Read article here.

BNP, troponin I, and YKL-40 as screening markers in extremely preterm infants at risk for pulmonary hypertension associated with bronchopulmonary dysplasia

Claudia Nold et al. published in the American Journal of Physiology Lung Cellular and Molecular Physiology.

Read article here.

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus

Jim Harris, Eric Morand et al. published in Scientific Reports.

Read article here.

A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage

Claudia Nold-Petry et al. published in Nature Immunology.

Read article here.

Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1Ra

Claudia Nold et al. published in the American Journal of Respiratory Cell and Molecular Biology.

Read article here.

The immunological landscape in necrotising enterocolitis

Claudia Nold et al. published in Expert reviews in molecular medicine.

Read article here.

Suppression of innate inflammation and immunity by interleukin-37

Claudia Nold-Petry et al. published in the European Journal of Immunology.

Read article here.